Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience

Lung Cancer

Volumn 73, Issue 3, 2011, Pages 351-355

  Pasello, Giulia ^a   Nicotra, Samuele ^b   Marulli, Giuseppe ^b   Rea, Federico ^b   Bonanno, Laura ^a   Carli, Paolo ^a   Magro, Cristina ^a   Jirillo, Antonio ^a   Favaretto, Adolfo ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Clinical benefit; Gemcitabine; Malignant pleural mesothelioma; Platinum based chemotherapy; Second line treatment; Third line treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PEMETREXED;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DECORTICATION; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; LEUKOPENIA; MALE; MALIGNANT PLEURA MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LEUKOPENIA; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLATINUM COMPOUNDS; PLEURAL NEOPLASMS; THROMBOCYTOPENIA;

EID: 79960890751     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.005     Document Type: Article

References (26)

1. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23(28):6881-6889.
2. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
3. Ceresoli G.L., Zucali P.A., Gianoncelli L., Lorenzi E., Santoro A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010, 36(1):24-32.
4. van Haarst J.M., Baas P., Manegold C., Schouwink J.H., Burgers J.A., de Bruin H.G., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002, 86(3):342-345.
5. Nowak A.K., Byrne M.J., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002, 87(5):491-496.
6. de Perrot M., Feld R., Cho B.C., Bezjak A., Anraku M., Burkes R., et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009, 27(9):1413-1418.
7. Kalmadi S.R., Rankin C., Kraut M.J., Jacobs A.D., Petrylak D.P., Adelstein D.J., et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008, 60(2):259-263.
8. Castagneto B., Zai S., Dongiovanni D., Muzio A., Bretti S., Numico G., et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005, 28(3):223-226.
9. Favaretto A.G., Aversa S.M., Paccagnella A., de Pangher-Manzini V., Palmisano V., Oniga F., et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003, 97(11):2791-2797.
10. Rea F., Marulli G., Bortolotti L., Breda C., Favaretto A.G., Loreggian L., et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer 2007, 57(1):89-95.
11. Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16(6):923-927.
12. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15(2):257-260.
13. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
14. Jassem J., Ramlau R., Santoro A., Schuette W., Chemaissani A., Hong S., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26(10):1698-1704.
15. Janne P.A., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J., Polikoff J.A., et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006, 1(6):506-512.
16. Sorensen J.B., Sundstrom S., Perell K., Thielsen A.K. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007, 2(2):147-152.
17. Taylor P., Castagneto B., Dark G., Marangolo M., Scagliotti G.V., van Klaveren R.J., et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008, 3(7):764-771.
18. Reck M., Stahel R.A., von Pawel J., Karthaus M., Korfee S., Serke M., et al. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. Respir Med 2010, 104(1):142-148.
19. Razak A.R., Chatten K.J., Hughes A.N. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer 2008, 60(2):294-297.
20. Serke M., Bauer T. Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma. J Clin Oncol 2007, 25(18S):18198. Abstract.
21. De Vincenzo F., Zucali P.A., Ceresoli G.L., Simonelli M., Gianoncelli L., Lorenzi E., et al. Re-treatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma (MPM): an observational study. Proceedings of the IX international conference of the IMIG (International Mesothelioma Interest Group) 2008, Abstract 163.
22. Xanthopoulos A., Bauer T.T., Blum T.G., Kollmeier J., Schonfeld N., Serke M. Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 2008, 3:34.
23. Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112(7):1555-1561.
24. Fennell D., Steele J., Sheaff M., Evans M., Shamash J., Wells M., et al. Response of malignant pleural mesothelloma to chemotherapy does not confer a survival advantage. Lung Cancer 2005, 49(S220). Abstract P-397.
25. Pasello G., Favaretto A. Molecular targets in malignant pleural mesothelioma treatment. Curr Drug Targets 2009, 10(12):1235-1244.
26. Fumagalli M., d'Adda di Fagagna F. SASPense and DDRama in cancer and ageing. Nat Cell Biol 2009, 11(8):921-923.